Single-cell RNA sequencing continues to expand, enabling detailed cellular atlases and understanding of disease heterogeneity, with international consortia like the Human Cell Atlas driving large data generation. Cheaper sequencing from newcomers such as Ultima Genomics supports the growth of single-cell experiments, unlocking data scale necessary for AI-driven biology. AI-powered platforms are maturing in pre-clinical drug discovery, as exemplified by Mount Sinai’s new AI Small Molecule Drug Discovery Center focusing on computational approaches to accelerate therapeutic development.